Figure 1.
Sublingual challenge tests with increasing doses of rMal d 1. The percentage of 72 birch pollen‐allergic patients developing oral allergy syndromes (OAS) upon sublingual challenge with indicated doses of rMal d 1 is shown; challenges were stopped when OAS occurred.